Clinical and Market Analysis of NanoBEO: A Public-Worth, Innovative Therapy for Behavioral and Psychological Symptoms of Dementia (BPSD)-Emerging Evidence and Its Implications for a Health Technology Assessment (HTA) and Decision-Making in National Health Systems
Background: According to scientific literature, some 99% of patients affected by Alzheimer's disease (AD) suffer from behavioral and psychological symptoms of dementia (BPSD), also known as neuropsychiatric symptoms (NPSs). In particular, agitation is one of the most difficult disorders to trea...
Saved in:
Main Authors: | Damiana Scuteri (Author), Daniele Pierobon (Author), Martina Pagliaro (Author), Kengo Hamamura (Author), Takafumi Hayashi (Author), Loris Pignolo (Author), Pierluigi Nicotera (Author), Giacinto Bagetta (Author), Maria Tiziana Corasaniti (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of therapeutic intervention with NanoBEO to manage agitation and pain in patients suffering from severe dementia: a pilot clinical trial
by: Damiana Scuteri, et al.
Published: (2024) -
Development and Translation of NanoBEO, a Nanotechnology-Based Delivery System of Bergamot Essential Oil Deprived of Furocumarins, in the Control of Agitation in Severe Dementia
by: Damiana Scuteri, et al.
Published: (2021) -
Dementia and COVID-19: A Case Report and Literature Review on Pain Management
by: Damiana Scuteri, et al.
Published: (2022) -
Epigenetic and nanotechnology alliance to fight stroke-induced brain damage
by: Giacinto Bagetta, et al.
Published: (2024) -
Editorial: "Novel Pain Therapeutics: From Basic Research to Clinical Translation and Rehabilitation"
by: Damiana Scuteri, et al.
Published: (2021)